Stocks Under Consideration: MGIC Investment Corporation (MTG), Merck & Co., Inc. (MRK), Sanchez Energy Corporation (SN)

MGIC Investment Corporation (MTG) grew with the stock adding 3.01% or $0.3 to close at $10.27 on active trading volume of 8.32M compared its three months average trading volume of 5.28M. The Milwaukee Wisconsin 53202 based company operating under the Property & Casualty Insurance industry has been trending up for the last 52 weeks, with the shares price now 40.11% up for the period and up by 0.79% so far this year. With price target of $11.4 and a 91.6% rebound from 52-week low, MGIC Investment Corporation has plenty of upside potential, making it a hold with a view buy.

MGIC Investment Corporation, through its subsidiaries, provides private mortgage insurance and ancillary services to lenders and government sponsored entities in the United States. The company offers primary mortgage insurance that provides mortgage default protection on individual loans, as well as covers unpaid loan principal, delinquent interest, and various expenses associated with the default and subsequent foreclosure. It also provides contract underwriting services; and other services for the mortgage finance industry, such as analysis of loan originations and portfolios, and mortgage lead generation services. In addition, the company participates in external reinsurance arrangements and captive mortgage reinsurance arrangements. It serves originators of residential mortgage loans, including savings institutions, commercial banks, mortgage brokers, credit unions, mortgage bankers, and other lenders. The company was founded in 1957 and is headquartered in Milwaukee, Wisconsin.

Merck & Co., Inc. (MRK) had a active trading with around 8.12M shares changing hands compared to its three month average trading volume of 11.12M. The stock traded between $61.08 and $61.78 before closing at the price of $61.17 with -0.5% change on the day. The Kenilworth New Jersey 07033 based company is currently trading 31.64% above its 52 week low of $47.97 and -5.84% below its 52 week high of $65.46. Both the RSI indicator and target price of  and $0 respectively, lead us to believe that it could rise over the coming weeks.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Sanchez Energy Corporation (SN) saw its value increase by 0.76% as the stock gained $0.1 to finish the day at a closing price of $13.3. The stock was higher in trading and has fluctuated between $2.06-$13.68 per share for the past year. The shares, which traded within a range of $12.71 to $13.66 during the day, are up by 85.24% in the past three months and up by 108.14% over the past six months. It is currently trading 39.44% above its 20 day moving average and 55.97% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $9.3 a share over the next twelve months. The current relative strength index (RSI) reading is 79.35.The technical indicator do not lead us to believe the stock will see more gains any time soon.

Sanchez Energy Corporation, an independent exploration and production company, engages in the exploration, acquisition, and development of oil and natural gas resources in the onshore U.S. Gulf Coast. It holds a 93% working interest in the Eagle Ford Shale, which consists of approximately 200,000 net leasehold acres in the oil and condensate, or black oil and volatile oil located in South Texas; and a 65% working interest in the Tuscaloosa Marine Shale covering an area of approximately 62,000 net leasehold acres situated in Mississippi and Louisiana. The company was founded in 2011 and is headquartered in Houston, Texas.

 

Traders Watch list: Merck & Co., Inc. (MRK), Comcast Corporation (CMCSA), Xerox Corporation (XRX)

Merck & Co., Inc. (MRK) saw its value decrease by -1.38% as the stock dropped $-0.86 to finish the day at a closing price of $61.48. The stock was lighter in trading and has fluctuated between $47.97-$65.46 per share for the past year. The shares, which traded within a range of $61.2 to $62.07 during the day, are down by -0.3% in the past three months and up by 5.74% over the past six months. It is currently trading 1.63% above its 20 day moving average and 1.02% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $0 a share over the next twelve months. The current relative strength index (RSI) reading is 53.12.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Comcast Corporation (CMCSA) shares were down in last trading by -0.29% to $72.56. It experienced lighter than average volume on day. The stock increased in value by almost 2.44% over the past week and grew 4.04% in the past month. It is currently trading 6.17% above its 50 day moving average and 11.81% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -0.52% decrease in value from its one year high of $72.94. The RSI indicator value of 70.38, lead us to believe that it may reverse gains in the near term.

Comcast Corporation operates as a media and technology company worldwide. It operates through Cable Communications, Cable Networks, Broadcast Television, Filmed Entertainment, and Theme Parks segments. The Cable Communications segment offers video, high-speed Internet, and voice services to residential and business customers under the XFINITY brand. This segment also provides business services, such as Ethernet network services; cellular backhaul services to mobile network operators; and advertising services on cable networks, as well as on other platforms, such as digital, radio, and print media. The Cable Networks segment operates national cable networks, which provide entertainment, news and information, and sports content; regional sports and news networks; international cable networks; and cable television studio production operations, as well as owns various digital media properties, which primarily include brand-aligned Websites. The Broadcast Television segment operates NBC and Telemundo broadcast networks, NBC and Telemundo owned local broadcast television stations, broadcast television studio production operations, and related digital media properties. The Filmed Entertainment segment produces, acquires, markets, and distributes live-action and animated filmed entertainment, principally under the Universal Pictures, Illumination, and Focus Features names. This segment also develops, produces, and licenses stage plays. The Theme Parks segment operates Universal theme parks in Orlando, Florida, as well as in Hollywood, California; Universal studios theme park in Osaka, Japan; Wet ‘n Wild, a water park in Orlando, Florida; and CityWalk, a dining, retail, and entertainment complex. The company also owns the Philadelphia Flyers, as well as the Wells Fargo Center arena in Philadelphia, Pennsylvania; and operates arena management-related businesses. Comcast Corporation was founded in 1963 and is headquartered in Philadelphia, Pennsylvania.

Xerox Corporation (XRX) traded within a range of $6.88 to $7.05 after opening the day at $7.04. The company has seen its stock increase in value by 20.52% so far this year. The stock was down close to -1.7% on light volume in last trading session and closed at $6.93 per share. After the recent fall, the stock is currently holding -5.29% below its 52 week high of $11.39 and 28.15% above its 12-month low of $6.46. The shares are up by over 9.95% in the last three months, and the RSI indicator value of 63.51 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Xerox Corporation provides business process and document management solutions worldwide. Its Services segment offers business process outsourcing services, such as customer care, transaction processing, finance and accounting, human resources, communication and marketing, and consulting and analytics services, as well as services in the areas of healthcare, transportation, financial services, retail, and telecommunications areas. This segment also provides document outsourcing services comprising managed print services, including workflow automation and centralized print services. The company’s Document Technology segment offers desktop monochrome and color printers, multifunction printers, copiers, digital printing presses, and light production devices; and production printing and publishing systems for the graphic communications marketplace and large enterprises. Its Other segment sells paper, wide-format systems, global imaging systems network integration solutions, and electronic presentation systems. The company sells its products and services directly to its customers; and through its sales force, as well as through a network of independent agents, dealers, value-added resellers, systems integrators, and the Web. Xerox Corporation was founded in 1906 and is headquartered in Norwalk, Connecticut.

 

Momentum Stocks in Focus: Merck & Co., Inc. (MRK), Cliffs Natural Resources Inc. (CLF), InterCloud Systems, Inc. (ICLD)

Merck & Co., Inc. (MRK) continued its upward trend with the stock climbing 0.21% or $0.13 to close the day at $62.34 on active trading volume of 9.95M shares, compared to its three month average trading volume of 11.27M. The Kenilworth New Jersey 07033 based company has been outperforming the drug manufacturers – major group over the past 52 weeks, with the stock gaining 24.23%, compared to the industry which has advanced 6.18% over the same period. With RSI of 59.93, the stock should still continue to rise and get closer to its one year target estimate of $0, making it a hold for now.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Cliffs Natural Resources Inc. (CLF) retreated with the stock falling -3.15% or $-0.3 to close at $9.23 on active trading volume of 9.9M compared its three months average trading volume of 14.11M. The Cleveland Ohio 44114 based company operating under the Industrial Metals & Minerals industry has been trending up for the last 52 weeks, with the shares price now 578.68% up for the period and up by 9.75% so far this year. With price target of $8 and a 656.56% rebound from 52-week low, Cliffs Natural Resources Inc. has plenty of upside potential, making it a hold with a view buy.

Cliffs Natural Resources Inc., a mining and natural resources company, produces and supplies iron ore. The company operates five iron ore mines in Michigan and Minnesota; and Koolyanobbing iron ore mining complex located in Western Australia, which produces lump and fines iron ore. It also own two iron ore mines in Eastern Canada. Cliffs Natural Resources Inc. sells its iron products to integrated steel companies and steel producers in the United States, China, Canada, and internationally. The company was formerly known as Cleveland-Cliffs Inc. Cliffs Natural Resources Inc. was founded in 1847 and is headquartered in Cleveland, Ohio.

InterCloud Systems, Inc. (ICLD) managed to rebound with the stock declining 2.11% or $0 to close the day at $0.02 on higher than average trading volume of 9.78M shares, compared to its three month average trading volume of 2.94M. The Shrewsbury New Jersey 07702 based company has been outperforming the information technology services companies by -73.9596% for last three months and its recent losses have pulled the stock down -37.62% YTD, versus the information technology services industry which is up 1.9% for the same period. The RSI of 32.49 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

InterCloud Systems, Inc. provides end-to-end IT and network solutions to the telecommunications service provider and corporate enterprise markets through cloud platforms and professional services in the United States and internationally. It operates through four segments: Applications and Infrastructure, Professional Services, Managed Services, and Cloud Services. The company offers various services, including platform as a service, infrastructure as a service, database as a service, and software as a service; and network management, 24x7x365 monitoring, security monitoring, and storage and backup services. It also provides software-defined networking (SDN) training, SDN software development and integration, virtualized network functions validation in a multi-vendor environment, unified communications, interactive voice response, and session initiation protocol based call centers, as well as structured cabling and other field installations. In addition, the company designs, engineers, installs, and maintains various types of Wi-Fi and wide-area, distributed antenna system, and small cell distribution networks for incumbent local exchange carriers, telecommunications original equipment manufacturers (OEMs), cable broadband multiple system operators, and enterprise customers, as well as designs, installs, and maintains hardware solutions for the OEMs that support voice, data, and optical networks. Further, it provides consulting and professional staffing solutions to the service-provider and enterprise market in support of IT and next-generation networks comprising project management, network implementation, network installation, network upgrades, rebuilds, maintenance, and consulting services. Additionally, the company’s engineering, design, installation, and maintenance services support the build-out and operation of enterprise, fiber optic, Ethernet, and wireless networks. InterCloud Systems, Inc. was founded in 2006 and is based in Shrewsbury, New Jersey.

 

3 Notable Runners: Merck & Co., Inc. (MRK), Immune Pharmaceuticals, Inc. (IMNP), Citigroup Inc. (C)

Merck & Co., Inc. (MRK) continued its upward trend with the stock climbing 0.94% or $0.58 to close the day at $62.21 on higher than average trading volume of 24.83M shares, compared to its three month average trading volume of 11.02M. The Kenilworth New Jersey 07033 based company has been underperforming the drug manufacturers – major companies by 1.6817% for last three months and its recent gains have pushed the stock slightly up 5.67% YTD, versus the drug manufacturers – major industry which is up 0.83% for the same period. The RSI of 59.05 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Immune Pharmaceuticals, Inc. (IMNP) had a light trading with around 23.36M shares changing hands compared to its three month average trading volume of 5.61M. The stock traded between $0.192 and $0.238 before closing at the price of $0.2 with 1.03% change on the day. The New York New York 10016 based company is currently trading 26.37% above its 52 week low of $0.155 and -69.85% below its 52 week high of $0.779. Both the RSI indicator and target price of 52.16 and $3 respectively, lead us to believe that it should be put on hold over the coming weeks.

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas. The company’s lead product candidate is Bertilimumab, a human monoclonal antibody, which is in Phase II clinical trial for the treatment of ulcerative colitis, bullous pemphigoid, and Crohn’s disease. It is also developing NanoCyclo, a topical nanocapsule formulation of cyclosporine, for the treatment of psoriasis and atopic dermatitis; Ceplene, a small molecule, which has completed Phase III clinical trials targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies; Azixa, a Phase II clinical trial novel microtubular destabilizer that functions as a vascular disruption agent; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer, which is in Phase II clinical trials for the treatment of patients with solid tumors. The company’s products also include NanomAbs technology platform, an antibody-drug conjugate platform for the treatment of cancer; novel technology platform for the construction of bispecific antibodies for immunotherapies; and AmiKet, a prescription topical analgesic cream, which is in Phase III clinical trial to treat peripheral neuropathies. It has license, and other collaborative research and development arrangements with BioNanoSim Ltd.; Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.; Atlante Biotech SAS; Shire Biochem, Inc.; Lonza Sales AG; MabLife SAS; iCo Therapeutics Inc.; Dalhousie University; and Endo Pharmaceuticals Inc. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in New York, New York.

Citigroup Inc. (C) traded within a range of $58.76 to $59.82 after opening the day at $59.53. The company has seen its stock decrease in value by -0.34% so far this year. The stock was down close to -1.22% on active volume in last trading session and closed at $59.23 per share. After the recent fall, the stock is currently holding -3.89% below its 52 week high of $61.63 and 72.96% above its 12-month low of $34.52. The shares are up by over 22.02% in the last three months, and the RSI indicator value of 50.58 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Citigroup Inc., a diversified financial services holding company, provides various financial products and services for consumers, corporations, governments, and institutions worldwide. It operates through two segments, Citicorp and Citi Holdings. The Citicorp segment offers traditional banking services to retail customers through retail banking, commercial banking, Citi-branded cards, and Citi retail services. This segment also provides various banking, credit card lending, and investment services through a network of local branches, offices, and electronic delivery systems. In addition, it offers wholesale banking products and services to corporate, institutional, public sector, and high-net-worth clients. Further, this segment provides fixed income and equity sales and trading, foreign exchange, prime brokerage, derivative services, equity and fixed income research, corporate lending, investment banking and advisory services, private banking, cash management, trade finance, and securities services. As of December 31, 2015, it operated 2,994 branches in 24 countries. The Citi Holdings segment provides consumer loans; portfolio of securities, loans, and other assets; and retail alternative investment and other services. Citigroup Inc. was founded in 1812 and is based in New York, New York.

 

Investor’s Alert: Merck & Co., Inc. (MRK), Sarepta Therapeutics, Inc. (SRPT), Kinder Morgan, Inc. (KMI)

Merck & Co., Inc. (MRK) failed to extend gains with the stock declining -1.93% or $-1.18 to close the day at $59.92 on higher than average trading volume of 15.15M shares, compared to its three month average trading volume of 10.8M. The Kenilworth New Jersey 07033 based company has been underperforming the drug manufacturers – major companies by -5.4901% for last three months and its recent losses have trimmed gains to 1.78% YTD, versus the drug manufacturers – major industry which is up 2.24% for the same period. The RSI of 44.33 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Sarepta Therapeutics, Inc. (SRPT) had a light trading with around 14.82M shares changing hands compared to its three month average trading volume of 2.39M. The stock traded at the price of $37.89 with 21.21% change on the day. The Cambridge Massachusetts 02142 based company is currently trading 373.62% above its 52 week low of $8 and -40.55% below its 52 week high of $63.73. Both the RSI indicator and target price of 67.47 and $64.33 respectively, lead us to believe that it should be put on hold over the coming weeks.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company’s lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Kinder Morgan, Inc. (KMI) traded within a range of $21.49 to $21.8 after opening the day at $21.74. The company has seen its stock increase in value by 4.15% so far this year. The stock was down close to -0.32% on active volume in last trading session and closed at $21.57 per share. After the recent fall, the stock is currently holding -7.11% below its 52 week high of $23.36 and 98.03% above its 12-month low of $11.2. The shares are up by over 1.3% in the last three months, and the RSI indicator value of 54.43 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Kinder Morgan, Inc. operates as an energy infrastructure company in North America. It operates through Natural Gas Pipelines, CO2, Terminals, Products Pipelines, Kinder Morgan Canada, and Other segments. The Natural Gas Pipelines segment owns and operates interstate and intrastate natural gas pipeline and storage systems; natural gas and crude oil gathering systems, and natural gas processing and treating facilities; natural gas liquids fractionation facilities and transportation systems; and liquefied natural gas facilities. The CO2 segment produces, transports, and markets CO2 for use in enhanced oil recovery projects; and owns interests in oil-producing fields, gas processing plants, and crude oil pipelines in the Permian Basin region of West Texas. The Terminals segment owns and operates liquids and bulk terminals that transload and store refined petroleum products, crude oil, and condensate, as well as bulk products, including coal, petroleum coke, cement, alumina, salt, and other bulk chemicals; and owns and operates tankers. The Products Pipelines segment owns and operates refined petroleum products, and crude oil and condensate pipelines; and associated product terminals and petroleum pipeline transmix facilities. The Kinder Morgan Canada segment owns and operates Trans Mountain pipeline system that transports crude oil and refined petroleum products from Edmonton, Alberta, and Canada to marketing terminals and refineries in British Columbia, Canada, and Washington; and jet fuel aviation turbine fuel pipeline that serves the Vancouver (Canada) International Airport. The Other segment includes various physical natural gas contracts with power plants. Kinder Morgan, Inc. owns interests in or operates approximately 84,000 miles of pipelines and 180 terminals. The company was formerly known as Kinder Morgan Holdco LLC and changed its name to Kinder Morgan, Inc. in February 2011. Kinder Morgan, Inc. was founded in 1936 and is headquartered in Houston, Texas.

 

Stocks on the Move: Merck & Co., Inc. (MRK), Medtronic plc (MDT), Regions Financial Corporation (RF)

Merck & Co., Inc. (MRK) continued its upward trend with the stock climbing 1.38% or $0.83 to close the day at $61.1 on active trading volume of 9.73M shares, compared to its three month average trading volume of 10.82M. The Kenilworth New Jersey 07033 based company has been outperforming the drug manufacturers – major group over the past 52 weeks, with the stock gaining 23.48%, compared to the industry which has advanced 8.16% over the same period. With RSI of 57.05, the stock should still continue to rise and get closer to its one year target estimate of $67.28, making it a hold for now.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Medtronic plc (MDT) climbed 1.3% during last trading as the stock added $0.95 to finish the day at $73.82 with about 9.67M shares changing hands, compared to its three month average trading volume of 6.52M. The $101.87B market cap company, which fluctuated between $73.2 and $74.11 during the day, currently situated 6.45% above its 52 week low of $69.35 and -16.81% away from its one year high of $89.27. The RSI of 51.75 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Medtronic plc manufactures and sells device-based medical therapies worldwide. The company’s Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators and cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular intervention products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment provides gastrointestinal diagnostics, ablation, and interventional lung solutions; stapling, vessel sealing, and other surgical instruments; sutures; electrosurgery products; hernia mechanical devices; mesh implants; products for patient monitoring and recovery; sensors; monitors; compression and dialysis, enteral feeding, and wound care products; and operating room supplies, electrodes, needles, syringes, and sharps disposals. The company’s Restorative Therapies Group segment offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, throat, and neurological disorders; systems that incorporate advanced energy surgical instruments; products for haemostatic sealing of soft tissue and bone; and image-guided surgery and intra-operative imaging systems. Its Diabetes Group segment provides insulin pumps and consumables; continuous glucose monitoring systems; and Web-based therapy management software solutions. It serves hospitals, physicians, clinicians, and patients. Medtronic plc was founded in 1949 and is headquartered in Dublin, Ireland.

Regions Financial Corporation (RF) saw its value decrease by -0.76% as the stock dropped $-0.11 to finish the day at a closing price of $14.37. The stock was lighter in trading and has fluctuated between $7-$14.73 per share for the past year. The shares, which traded within a range of $14.21 to $14.47 during the day, are up by 39.75% in the past three months and up by 69.56% over the past six months. It is currently trading -0.53% below its 20 day moving average and 8.91% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $14.48 a share over the next twelve months. The current relative strength index (RSI) reading is 59.82. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Regions Financial Corporation, together with its subsidiaries, provides banking and bank-related services to individual and corporate customers in the United States. Its Corporate Bank segment offers commercial banking services, such as commercial and industrial, commercial real estate, and investor real estate lending, as well as equipment lease financing services. This segment serves corporate, middle market, small business, and commercial real estate developers and investors. The company’s Consumer Bank segment provides consumer banking products and services related to residential first mortgages, home equity lines and loans, small business loans, indirect loans, consumer credit cards, and other consumer loans, as well as the corresponding deposit relationships. Its Wealth Management segment offers wealth management products and services, including credit related products, trust and investment management, asset management, retirement and savings solutions, estate planning, and personal and commercial insurance products to individuals, businesses, governmental institutions, and non-profit entities. The company also provides insurance coverage for various lines of personal and commercial insurance, such as property, vehicle, casualty, life, health, and accident insurance, as well as commercial crop, life, and environmental insurance; and commercial equipment financing products, as well as offers securities, insurance, and advisory services through financial consultants. In addition, it offers securities brokerage, merger and acquisition advisory, trust, and other specialty financing services. As of December 31, 2015, the company operated 1,627 banking offices and 1,962 ATMs in Alabama, Arkansas, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana, Mississippi, Missouri, North Carolina, South Carolina, Tennessee, Texas, and Virginia. Regions Financial Corporation was founded in 1971 and is headquartered in Birmingham, Alabama.

 

Momentum Stocks in Focus: The Coca-Cola Company (KO), Merck & Co., Inc. (MRK), Bristol-Myers Squibb Company (BMY)

The Coca-Cola Company (KO) failed to extend gains with the stock declining -0.02% or $-0.01 to close the day at $41.74 on light trading volume of 10.25M shares, compared to its three month average trading volume of 13.67M. The Atlanta Georgia 30313 based company has been outperforming the beverages – soft drinks group over the past 52 weeks, with the stock gaining 3.55%, compared to the industry which has advanced 5.69% over the same period. With RSI of 52.73, the stock should still continue to rise and get closer to its one year target estimate of $45.54, making it a hold for now.

The Coca-Cola Company, a beverage company, manufactures and distributes various nonalcoholic beverages worldwide. The company primarily offers sparkling beverages and still beverages. Its sparkling beverages include nonalcoholic ready-to-drink beverages with carbonation, such as carbonated energy drinks, and carbonated waters and flavored waters. The company’s still beverages comprise nonalcoholic beverages without carbonation, including noncarbonated waters, flavored and enhanced waters, noncarbonated energy drinks, juices and juice drinks, ready-to-drink teas and coffees, and sports drinks. It also provides flavoring ingredients, sweeteners, beverage ingredients, and fountain syrups, as well as powders for purified water products. The Coca-Cola Company sells its products primarily under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero, Fanta, Sprite, Minute Maid, Georgia, Powerade, Del Valle, Schweppes, Aquarius, Minute Maid Pulpy, Dasani, Simply, Glacéau Vitaminwater, Bonaqua/Bonaqa, Gold Peak, FUZE TEA, Glacéau Smartwater, and Ice Dew brand names. The company offers its beverage products through a network of company-owned or controlled bottling and distribution operators, as well as through independent bottling partners, distributors, wholesalers, and retailers. The Coca-Cola Company was founded in 1886 and is headquartered in Atlanta, Georgia.

Merck & Co., Inc. (MRK) grew with the stock adding 0.27% or $0.16 to close at $60.27 on light trading volume of 10.24M compared its three months average trading volume of 10.84M. The Kenilworth New Jersey 07033 based company operating under the Drug Manufacturers – Major industry has been trending up for the last 52 weeks, with the shares price now 19.74% up for the period and up by 2.38% so far this year. With price target of $67.28 and a 29.7% rebound from 52-week low, Merck & Co., Inc. has plenty of upside potential, making it a hold with a view buy.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Bristol-Myers Squibb Company (BMY) failed to extend gains with the stock declining -0.3% or $-0.18 to close the day at $59.95 on lower than average trading volume of 10.1M shares, compared to its three month average trading volume of 11.56M. The New York New York 10154 based company has been underperforming the drug manufacturers – major companies by 9.6422% for last three months and its recent gains have pushed the stock slightly up 3.26% YTD, versus the drug manufacturers – major industry which is up 2.04% for the same period. The RSI of 68.56 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

 

Stocks Intraday Alert: Merck & Co., Inc. (MRK), The Coca-Cola Company (KO), Rennova Health, Inc. (RNVA)

Merck & Co., Inc. (MRK) continued its downward trend with the stock declining -0.03% or $-0.02 to close the day at $60.11 on higher than average trading volume of 9M shares, compared to its three month average trading volume of 10.82M. The Kenilworth New Jersey 07033 based company has been underperforming the drug manufacturers – major companies by -3.528% for last three months and its recent losses have trimmed gains to 2.11% YTD, versus the drug manufacturers – major industry which is up 2.59% for the same period. The RSI of 51.1 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

The Coca-Cola Company (KO) had a active trading with around 8.97M shares changing hands compared to its three month average trading volume of 13.68M. The stock traded between $41.53 and $41.86 before closing at the price of $41.75 with 0.24% change on the day. The Atlanta Georgia 30313 based company is currently trading 5.78% above its 52 week low of $39.88 and -9.25% below its 52 week high of $47.13. Both the RSI indicator and target price of 54.64 and $45.54 respectively, lead us to believe that it should be put on hold over the coming weeks.

The Coca-Cola Company, a beverage company, manufactures and distributes various nonalcoholic beverages worldwide. The company primarily offers sparkling beverages and still beverages. Its sparkling beverages include nonalcoholic ready-to-drink beverages with carbonation, such as carbonated energy drinks, and carbonated waters and flavored waters. The company’s still beverages comprise nonalcoholic beverages without carbonation, including noncarbonated waters, flavored and enhanced waters, noncarbonated energy drinks, juices and juice drinks, ready-to-drink teas and coffees, and sports drinks. It also provides flavoring ingredients, sweeteners, beverage ingredients, and fountain syrups, as well as powders for purified water products. The Coca-Cola Company sells its products primarily under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero, Fanta, Sprite, Minute Maid, Georgia, Powerade, Del Valle, Schweppes, Aquarius, Minute Maid Pulpy, Dasani, Simply, Glacéau Vitaminwater, Bonaqua/Bonaqa, Gold Peak, FUZE TEA, Glacéau Smartwater, and Ice Dew brand names. The company offers its beverage products through a network of company-owned or controlled bottling and distribution operators, as well as through independent bottling partners, distributors, wholesalers, and retailers. The Coca-Cola Company was founded in 1886 and is headquartered in Atlanta, Georgia.

Rennova Health, Inc. (RNVA) traded within a range of $0.0824 to $0.0913 after opening the day at $0.09. The company has seen its stock increase in value by 3.37% so far this year. The stock was up close to 4.13% on active volume in last trading session and closed at $0.09 per share. After the recent gain, the stock is currently holding -93.35% below its 52 week high of $1.16 and 7.25% above its 12-month low of $0.0802. The shares are down by over -46.38% in the last three months, and the RSI indicator value of 43.04 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Rennova Health, Inc. provides diagnostics and supportive software solutions to healthcare providers in the United States. It offers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management solutions, as well as intends to provide financial services in the form of loans to physician practices. The company provides toxicology, clinical pharmacogenetics, and esoteric testing services; develops Web-based system to place lab orders, track samples, and view test reports in real time; Web-enabled laboratory information management solutions; Medical Mime, which offers an electronic health record for substance abuse and behavioral health providers; and CollabRx that enhances cancer diagnoses and treatment through actionable data analytics and reporting for oncologists and their patients. Rennova Health, Inc. was founded in 2005 and is headquartered in West Palm Beach, Florida.

 

Stocks Alert: Applied Materials, Inc. (AMAT), Merck & Co., Inc. (MRK), Exxon Mobil Corporation (XOM)

Applied Materials, Inc. (AMAT) grew with the stock adding 0.94% or $0.3 to close at $32.24 on active trading volume of 9.45M compared its three months average trading volume of 11.12M. The Santa Clara California 95054 based company operating under the Semiconductor Equipment & Materials industry has been trending up for the last 52 weeks, with the shares price now 77.25% up for the period and down by -0.09% so far this year. With price target of $35.28 and a 112.26% rebound from 52-week low, Applied Materials, Inc. has plenty of upside potential, making it a hold with a view buy.

Applied Materials, Inc. provides manufacturing equipment, services, and software to the semiconductor, display, and related industries worldwide. It operates through three segments: Semiconductor Systems, Applied Global Services, and Display and Adjacent Markets. The Semiconductor Systems segment develops, manufactures, and sells a range of manufacturing equipment used to fabricate semiconductor chips or integrated circuits. It offers products and technologies for transistor and interconnect fabrication, including epitaxy, ion implantation, oxidation and nitridation, rapid thermal processing, chemical vapor deposition, physical vapor deposition, chemical mechanical planarization, and electrochemical deposition; patterning, selective removal, and packaging products and systems that enable the transfer of patterns onto device structures; and metrology, inspection, and review systems for front- and back-end-of-line applications. The Applied Global Services segment provides integrated solutions to optimize equipment and fab performance and productivity, including spares, upgrades, services, remanufactured earlier generation equipment, and factory automation software for semiconductor, display, and other products. The Display and Adjacent Markets segment offers products for manufacturing liquid crystal displays, organic light-emitting diodes, and other display technologies for TVs, personal computers, tablets, smart phones, and other consumer-oriented devices, as well as equipment for flexible substrates. The company serves manufacturers of semiconductor wafers and chips, liquid crystal and other displays, and other electronic devices. Applied Materials, Inc. was founded in 1967 and is headquartered in Santa Clara, California.

Merck & Co., Inc. (MRK) dropped $-0.02 to close the day at a new closing price of $60.13, a -0.03% decrease in value from its previous closing price that moved the stock 29.4% above its 52 week low of $47.97. A total of 9.41M shares exchanged hands during the day compared with its three month average trading volume of 10.8M. The stock, which fluctuated between $60.04 and $60.79 during the day, currently situated -7.44% below its 52 week high. The stock is down by -0.88% in the past one month and down by -2.99% over the past three months. With a one year target estimate of $67.28 and RSI of 51.43, the stock still has upside potential, making it a hold for now.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has a collaboration agreement with Adaptimmune Therapeutics plc; and a research agreement with Proteros Biostructures to develop small molecule compounds for the treatment of various cancers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Exxon Mobil Corporation (XOM) shares were down in last trading by -1.1% to $89.89. It experienced lighter than average volume on day. The stock decreased in value by almost -0.95% over the past week and grew 3.27% in the past month. It is currently trading 2.88% above its 50 day moving average and 3.43% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -4.28% decrease in value from its one year high of $95.55. The RSI indicator value of 55.58, lead us to believe that it is a hold for now.

Exxon Mobil Corporation explores for and produces crude oil and natural gas in the United States, Canada/South America, Europe, Africa, Asia, and Australia/Oceania. It also manufactures and markets commodity petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics, and specialty products; and transports and sells crude oil, natural gas, and petroleum products. As of December 31, 2015, the company had approximately 35,909 gross and 30,114 net operated wells. Exxon Mobil Corporation was founded in 1870 and is headquartered in Irving, Texas.

 

Investor’s Watch List: HP Inc. (HPQ), Groupon, Inc. (GRPN), Merck & Co., Inc. (MRK)

HP Inc. (HPQ) had a active trading with around 12.5M shares changing hands compared to its three month average trading volume of 11.96M. The stock traded between $14.62 and $15.14 before closing at the price of $14.85 with 0.07% change on the day. The Palo Alto California 94304 based company is currently trading 73.07% above its 52 week low of $8.91 and -7.84% below its 52 week high of $16.25. Both the RSI indicator and target price of 43.12 and $16.1 respectively, lead us to believe that it should be put on hold over the coming weeks.

HP Inc. provides products, technologies, software, solutions, and services to individual consumers and small- and medium-sized businesses, as well as to the government, health, and education sectors worldwide. It operates through Personal Systems and Printing segments. The Personal Systems segment offers commercial personal computers (PCs), consumer PCs, workstations, thin clients, commercial tablets and mobility devices, retail point-of-sale systems, displays and other related accessories, software, support, and services for the commercial and consumer markets. The Printing segment provides consumer and commercial printer hardware, supplies, media, solutions, and services, as well as scanning devices; and laserjet and enterprise, inkjet and printing, graphics, and 3D printing solutions. The company was formerly known as Hewlett-Packard Company and changed its name to HP Inc. in October 2015. HP Inc. was founded in 1939 and is headquartered in Palo Alto, California.

Groupon, Inc. (GRPN) managed to rebound with the stock climbing 5.42% or $0.18 to close the day at $3.5 on light trading volume of 12.38M shares, compared to its three month average trading volume of 13.39M. The Chicago Illinois 60654 based company has been outperforming the internet information providers group over the past 52 weeks, with the stock gaining 16.67%, compared to the industry which has advanced 6.44% over the same period. With RSI of 42.3, the stock should still continue to rise and get closer to its one year target estimate of $5.13, making it a hold for now.

Groupon, Inc. operates online local commerce marketplaces that connect merchants to consumers by offering goods and services at a discount in North America, Europe, the Middle East, Africa, and internationally. It also provides deals on products for which it acts as the merchant of record. The company offers deals in various categories, including food and drink, events and activities, beauty and spa, health and fitness, home and garden, and automotive; and deals on various product lines, such as electronics, sporting goods, jewelry, toys, household items, and apparel, as well as provides discounted and market rates for hotel, airfare, and package deals. It offers its deal offerings to customers through Websites; search engines; and mobile applications and mobile browsers, which enable consumers to browse, purchase, manage, and redeem deals on their mobile devices, as well as sends emails to its subscribers with deal offerings that are targeted by location and personal preferences. The company was formerly known as ThePoint.com, Inc. and changed its name to Groupon, Inc. in October 2008. The company was founded in 2008 and is headquartered in Chicago, Illinois. Groupon, Inc. is a subsidiary of The Point, LLC.

Merck & Co., Inc. (MRK) shares were up in last trading by 2.17% to $60.15. It experienced higher than average volume on day. The stock increased in value by almost 0.99% over the past week and fell -0.24% in the past month. It is currently trading -0.93% below its 50 day moving average and 3.08% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -7.41% decrease in value from its one year high of $65.46. The RSI indicator value of 50.99, lead us to believe that it is a hold for now.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has a collaboration agreement with Adaptimmune Therapeutics plc; and a research agreement with Proteros Biostructures to develop small molecule compounds for the treatment of various cancers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.